Predictive factors of treatment outcomes after percutaneous ablation of hepatocellular carcinoma in the caudate lobe: a retrospective study

Table 5 Univariate and multivariate analysis of predictors of overall survival outcome after caudate lobe ablation in patients with HCC

Factors		Univariate	Multivariate
Factors		P value	HR	95%CI	P value
Gender(M/F)		0.880
Age(≤60/>60y)		0.917
Tumor type (naïve/recurrent)		0.137
Surgery history of liver (Y/N)		0.564
Etiology (Hepatitis/others)		0.315
Liver cirrhosis (Y/N)		0.229
Antiviral treatment (Y/N)		0.122
ECOG performance status (0/1)		0.877
Child-Pugh (A/B)		0.292
BCLC stage of primary HCC (A/B)		0.873
AFP (≥400/< 400 μg/L)		0.283
PLT (≥100/< 100 × 109/L)		0.529
PT (≤14/> 14 s)		0.901
ALB (≤35/> 35 g/L)		0.254
ALT (≤40/> 40 IU/L)		0.518
TB (≤17.1/> 17.1 mol/L)		0.886
Tumor number (single /multiple)		0.101
Location (Paracaval portion/ Caudate process/ Spiegel’s lobe)		0.069
Tumor size (≤2 cm /> 2 cm)		0.720
Puncture approach (LA/ RA/ combination approach)		0.809
Treatment strategy	RFA/ EA/ RFA-EA	0.960
	EA/RFA or RFA-EA	0.807
	RFA or EA/RFA-EA	0.529
AM (≥ 5 mm / < 5 mm)		0.189
LTP (Y/N)		0.890
Major complication (Y/N)		0.172

HBV hepatitis B virus, HCV hepatitis C virus, ECOG East Coast Oncology Group, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, PLT platelets, PT prothrombin time, ALB albumin, ALT alanine aminotransferase, TB total bilirubin, LA left lobe approach, RA right intercostal approach, EA ethanol ablation, RFA radiofrequency ablation, RFA-EA combination of RFA and EA, AM ablative margin, LTP local tumor progression

ISSN: 1471-2407